Search Results

Results for "/clinical/?page=3"

Nivolumab/Ipilimumab Improves OS in Unresectable Malignant Pleural Mesothelioma

August 10, 2020

Nivolumab in combination with ipilimumab significantly improved overall survival (OS) in treatment-naïve patients with unresectable malignant pleural mesothelioma (MPM) who were treated in the phase 3 CheckMate 743 clinical trial.

Enzastaurin and a Novel Biomarker Spark Optimism for All Risk Levels of DLBCL

August 09, 2020

In an interview with Targeted Oncology, Grzegorz S. Nowakowski, MD, discussed the promise of the enzastaurin in the diffuse large B-cell lymphoma treatment landscape and the ongoing phase 3 ENGINE study.

CS1001 Plus Chemotherapy Prolongs Progression-Free Survival in Stage IV NSCLC

August 07, 2020

The combination of CS1001 and chemotherapy led to an improvement in progression-free survival among patients with stage IV squamous and non-squamous non–small cell lung cancer, according to data from the phase 3 CS1001-302 clinical trial assessed by an Independent Data Monitoring Committee, achieving the study’s primary end point.

Frontline Atezolizumab Plus Paclitaxel Misses Primary End Point in TNBC Trial

August 07, 2020

The phase 3 IMpassion131 trial investigating atezolizumab plus paclitaxel versus placebo plus paclitaxel did not its primary end point of progression-free survival and was not statistically significant in the first line for patients with metastatic triple-negative breast cancer who had PD-L1-positive disease.

Lorlatinib Prolongs PFS Over Crizotinib in ALK+ NSCLC, Adds to Existing Data for FDA Submission

August 05, 2020

Lorlatinib demonstrated an improvement in progression-free survival compared with crizotinib as treatment of patients with treatment-naïve advanced ALK-positive non–small cell lung cancer, meeting the primary end point of the phase 3 CROWN trial.

OPTIMA Trial Will Continue to Follow Patients With HCC Treated With ThermoDox Combo

August 05, 2020

Patients with hepatocellular carcinoma, or primary liver cancer, treated with ThermoDox plus radiofrequency ablation in the phase 3 OPTIMA clinical trial will continue to be followed for overall survival.